AHA 2026 Cardiovascular Statistics: Key Clinical Takeaways
The 2026 AHA Heart Disease and Stroke Statistics Update reveals 915,973 CV deaths in 2023, stroke as the 4th leading cause of death, and a new CKM syndrome chapter. Key takeaways for clinicians.
Cardiovascular Risk in Women After Pregnancy Complications
Pregnancy complications — preeclampsia, gestational diabetes, preterm delivery — are now recognized as major predictors of lifelong cardiovascular risk in women. A 2026 review of the evidence, AHA guidelines, and post-pregnancy surveillance strategies.
Coronary CT Angiography for Chest Pain: CT-First Strategy in 2026
SCOT-HEART 10-year data confirms coronary CT angiography reduces MI by 21% when used to guide stable chest pain management. A 2026 review of the CT-first strategy, AI plaque analysis, and guideline recommendations.
Remote Cardiac Monitoring and Wearables in 2026
Remote patient monitoring with wearables is transforming cardiology — from AF detection on smartwatches to AI-driven HF decompensation prediction. A 2026 review of evidence, devices, clinical applications, and implementation guidance.
Early Rhythm Control in Atrial Fibrillation: 2026 Update
EAST-AFNET 4 transformed AF management by proving early rhythm control reduces cardiovascular events. A 2026 review of the evidence, pulsed field ablation, the 2024 ESC AF guidelines, and practical implementation.
HFpEF Treatment in 2026: New Therapeutic Pillars
HFpEF finally has its own therapeutic pillars. A 2026 review of SGLT2 inhibitors, finerenone (FINEARTS-HF), GLP-1 RAs (STEP-HFpEF, SUMMIT), and emerging combination strategies for heart failure with preserved ejection fraction.
TAVR in Low-Risk Aortic Stenosis: 2026 Clinical Review
5-year data from Evolut Low Risk and PARTNER 3 confirm TAVR is noninferior to surgery in low-risk aortic stenosis patients. A 2026 review of outcomes, durability, real-world evidence, and lifetime management considerations.
Renal Denervation for Resistant Hypertension in 2026
Renal denervation has re-emerged as a viable treatment for resistant hypertension after pivotal SPYRAL and RADIANCE trials. A 2026 clinical review of evidence, patient selection, and practical guidance.
AI ECG Diagnosis 2026: Accuracy, Clinical Use Cases & Limits
AI ECG diagnosis explained for 2026: accuracy, clinical use cases, arrhythmia detection, heart failure signals, workflow benefits, and key limitations doctors should know.
GLP-1 Receptor Agonists and Cardiovascular Outcomes in 2026
A comprehensive review of GLP-1 receptor agonists and their cardiovascular benefits beyond weight management, including MACE reduction, heart failure outcomes, and implications for clinical practice in 2026.